RP Bio Inc. (KOSDAQ:314140)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,950.00
+270.00 (4.75%)
At close: Jul 31, 2026

RP Bio Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
5,6034,682-907.125,4374,3163,813
Depreciation & Amortization
6,3106,4126,8186,0485,4035,203
Loss (Gain) From Sale of Assets
178.59178.599.24--150.064.31
Loss (Gain) From Sale of Investments
-9.22-1.59----
Stock-Based Compensation
----5.7710.5414.57
Provision & Write-off of Bad Debts
50.3294.032.70.09-26.95-36.16
Other Operating Activities
4,5053,3931,7942,1067,1493,781
Change in Accounts Receivable
3,645-1,1352,334777.83-1,651-4,355
Change in Inventory
-4,261-1,26710,2453,755-16,021-6,180
Change in Accounts Payable
493.22,098-3,406-9,0445,2529,117
Change in Other Net Operating Assets
-53.34-2,179-3,3661,505-3,125-1,902
Operating Cash Flow
16,46212,47613,52410,5801,1559,459
Operating Cash Flow Growth
1.63%-7.75%27.82%816.03%-87.79%46.55%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,816-5,200-5,853-11,123-5,147-7,246
Sale of Property, Plant & Equipment
19.5819.5814.3869.73165.55-
Sale (Purchase) of Intangibles
-371.37-411.27-157.78-41.02-132.18-24.59
Investment in Securities
5,574-1004,405-7,803-7.2308.64
Other Investing Activities
-1,676-1,675390.45-6.67-218.69-204.13
Investing Cash Flow
332.11-7,066-1,501-18,264-5,939-7,166

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-16,00021,000-14,50023,235
Total Debt Issued
16,00016,00021,000-14,50023,235
Short-Term Debt Repaid
--25,000-21,000-5,000-14,500-26,104
Long-Term Debt Repaid
--688.6-665.09-919.92-453-522.83
Total Debt Repaid
-21,646-25,689-21,665-5,920-14,953-26,627
Net Debt Issued (Repaid)
-5,646-9,689-665.09-5,920-453-3,392
Issuance of Common Stock
----16,287-
Dividends Paid
---432.49---
Other Financing Activities
500---3.79-502.46-
Financing Cash Flow
-5,146-9,689-1,098-5,92415,332-3,392

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-6.61-6.61----
Miscellaneous Cash Flow Adjustments
0--0---0
Net Cash Flow
11,641-4,28510,925-13,60810,547-1,099

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
12,6457,2767,670-543.31-3,9922,213
Free Cash Flow Growth
37.82%-5.14%----
Free Cash Flow Margin
9.21%5.34%6.19%-0.36%-2.89%1.93%
Free Cash Flow Per Share
1462.07841.15887.85-58.16-560.54336.69
Levered Free Cash Flow
7,7875,3026,556-6,112-3,592-1,246
Unlevered Free Cash Flow
8,2275,8207,338-4,990-2,852-633.95

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
705.34831.791,3161,816989.75638.38
Cash Income Tax Paid
506.47394.19439.62992.04246.9122.34
Change in Working Capital
-175.58-2,4825,807-3,006-15,546-3,321